Skip Navigation

Yale University/Yale New Haven Hospital

Section of Medical Oncology
20 York Street
SMILOW NP 11-406
New Haven, CT 06510
(203) 688-7557
(888) 700-6543
http://www.ynhh.org

Number of Transplants Performed

This center has been performing allogeneic transplants since 1987 and has been an NMDP transplant center since November 1999.

Transplants Reported (From Jan. 2011 to Dec. 2012 as reported by the centers)       Unrelated or Related Donor Auto-
logous

(PBSC or marrow)
Total (by transplant type)
Marrow PBSC Cord
Blood
Unrelated Donor
- Adult
3 49 0 --- 52
Unrelated Donor
- Pediatric
1 0 0 --- 1
Related Donor
- Adult
2 37 0 --- 39
Related Donor
- Pediatric
3 0 0 --- 3
Autologous
- Adult
--- --- --- 153 153
Autologous
- Pediatric
--- --- --- 1 1
Total
(by cell source)
9 86 0 154 249

To find centers that perform cord blood transplants, use the Search Tool on this site.


Patient Survival Information for this Center

Yale New Haven Hospital


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 126 patients.

The actual 1-year survival of these patients is 71.3%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 60.4% and 76.0%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).


Transplant Results by Patient's Age, Disease Type and Stage

Yale University/Yale New Haven Hospital - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- -- -- -- 2/2 1/1 0/1 3/4
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- -- 1/1 -- -- 1/1
Acute myelogenous leukemia in first complete remission -- 2/2 2/2 1/2 3/4 9/9 3/3 20/22
Acute myelogenous leukemia in second complete remission -- -- -- -- -- 2/2 0/1 2/3
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- 0/1 1/1 -- -- 1/2
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- -- 2/2 -- 2/2
Hodgkin lymphoma -- -- 1/1 -- -- 1/1 -- 2/2
Multiple myeloma / Plasma cell disorder -- -- -- -- 1/2 -- -- 1/2
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- 1/1 -- 0/2 -- -- 1/3
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- -- -- 1/1 1/1 2/2
Myeloproliferative syndromes -- -- -- -- -- -- 1/1 1/1
Non-Hodgkin lymphoma -- -- -- -- 1/1 3/4 2/4 6/9
Other acute leukemia -- -- -- -- -- 1/1 1/1 2/2
Severe aplastic anemia -- 1/1 -- -- 2/2 -- -- 3/3
Total -- 3/3 4/4 1/3 11/15 20/21 8/12 47/58

Yale University/Yale New Haven Hospital - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- -- 1/1 0/2 0/1 2/2 1/1 4/7
Acute lymphoblastic leukemia in second complete remission -- -- -- 0/1 1/1 -- 0/4 1/6
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 1/1 -- -- -- -- 1/1
Acute myelogenous leukemia in first complete remission -- -- 1/1 1/2 1/1 1/4 6/10 10/18
Acute myelogenous leukemia in second complete remission -- -- -- 0/1 -- 0/1 3/4 3/6
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- 1/1 -- -- 0/1 -- 1/1 2/3
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- -- 1/1 -- 1/1
Chronic myelogenous leukemia in first chronic phase -- -- 1/1 -- -- -- -- 1/1
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- -- -- 3/3 1/1 4/4
Myeloproliferative syndromes -- -- -- -- -- 1/1 -- 1/1
Non-Hodgkin lymphoma -- -- 2/3 1/1 1/1 6/7 3/5 13/17
Other acute leukemia -- -- -- -- 0/1 -- -- 0/1
Severe aplastic anemia -- -- 1/1 -- -- -- -- 1/1
Total -- 1/1 7/8 2/7 3/6 14/19 15/26 42/67

Program Description:

Myeloablative/non-myeloablative transplant approaches for patients with acute/chronic leukemia, MDS, lymphoma, MM, marrow failure and other MPF disorders. Interests include NHL, reduced-intensity regimen for older patients, and novel therapies to prevent and treat graft-versus-host disease (GVHD).

Contact Information:

If you have transplant-related questions, please contact Susan Faraone, transplant center coordinator, at (203) 200-6346 or by e-mail at susan.faraone@ynhh.org.

Program Type:

Adult and Pediatric

Attending Physicians:

(Medical Doctors)

Adult -

Dennis Cooper, Francine Foss, Iris Isufi, Stuart Seropian, Warren Shlomchik

Pediatric -

Deborah Chirnomas, Stephanie Massaro

Transplants Performed:

Marrow/PBSC only

Cord blood transplants performed on:

Not performed

Find research trials at this center here:

ClinicalTrials.gov

Estimated Search & Transplant Costs

The costs for a transplant vary greatly from center to center and depend on factors such as health insurance, disease type and disease stage of the patient, as well as center-specific billing policies. Examples of costs in the search and transplant include:

  • The amount and geographic location of donors tested
  • Testing needed to confirm a match
  • Processing and collecting of tissue-typing samples
  • Donor workup testing needed
  • Getting the marrow, PBSC or cord blood unit for transplant

For the best understanding of costs of transplant and follow-up for a specific transplant center, contact the center's Financial Representative.

help Explain Transplant Costs at Different Centers

Resources for financial information

If you have questions about costs and financial services at this transplant center, you can contact the center's financial representative, Susan Faraone by e-mail at susan.faraone@ynhh.org or by phone at (203) 200-6346.

Financial services at this center could include:

  • Health insurance information
  • Financial assistance
  • Patient-related resources

Additional Information

Further information about this center, including the number and type of transplants performed in each of the last three years, and the support groups offered, may be found in the BMT InfoNet Transplant Center Directory:
http://www.bmtinfonet.org/transplantcenters.

BMT InfoNet (Blood & Marrow Transplant Information Network) is a nonprofit organization that provides information and emotional support to transplant patients and their families.